Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon
about
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysisPharmacogenomics in Pediatric Patients: Towards Personalized MedicineCYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drugWarfarin pharmacogenetics.Gastroprotective efficacy and safety evaluation of scoparone derivatives on experimentally induced gastric lesions in rodentsPharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European Society of Pharmacogenomics and Theranostics) satellite symposium, May 2013.Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses.Warfarin Pharmacogenomics in Diverse Populations.Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.Heritability of metoprolol and torsemide pharmacokinetics.Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.Opportunities and limitations: the value of pharmacogenetics in clinical practice.Role of ABC transporters in trans-epithelial transport of vitamin K antagonists.Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.A commonly used Chinese herbal formula, Shu-Jing-Hwo-Shiee-Tang, potentiates anticoagulant activity of warfarin in a rabbit model.Patients benefit from genetics-guided coumarin anticoagulant therapy.Vitamin K deficiency: the linking pin between COPD and cardiovascular diseases?The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin.Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms.Management of anticoagulation in hip fractures: A pragmatic approach.Effects of anticoagulation therapy with vitamin K antagonists on hospitalizations and emergency room accesses in Grosseto (Italy).VKORC1 inhibitors binds VKORC1 dimer
P2860
Q27026134-79604298-AEBE-47E5-9608-E24D836EEED4Q28071448-E3D30FCD-578B-4308-A547-5C2725936552Q28544111-E5095B00-B8A8-4B71-AACE-B7A944FB75DDQ34785072-9183235A-F662-4BB4-A016-EE7102A5EFCCQ35227914-9F98C685-C8C9-4E8E-A915-C193E93322A2Q37155049-D2C01212-26CD-4FB3-A6DE-CB7A2DAA1F2DQ37222352-D0F6B629-18AD-4336-AABE-816D29A8E26AQ38261133-AD49E32A-65DA-4EE6-A787-FB50C6FF486CQ38321269-E864D2B9-1BA9-4F37-9F9B-E3AFAB93A093Q38427249-662A5750-55B2-4154-91D4-A5C41FD1948DQ38696567-3B12BE1D-5079-4249-AA75-E046528BCE4CQ38907884-430E53D4-0CA3-42F6-88C6-E2741817F661Q39034538-0AFF8809-6739-4DE6-B79D-D9D90EEAFF76Q39213540-CD7FB596-F97A-4316-952E-5784D9249268Q40425835-6EC205C0-DA10-4B69-95C0-ABF6F11B8E22Q41398712-D4A63A0F-82F6-4C72-9447-B0BEDC90FCE1Q41535294-C6E26267-A75D-4C03-854C-A517BCF439B4Q42383190-1425B1FD-7AC3-41EE-A019-519989945CF6Q42502722-50384812-E30E-4EB9-8B2B-FACD591D244FQ43926562-A83ED65A-92EE-44F6-8DE4-8E85202CFDF0Q44444244-E1233C44-3D1E-45E0-B3FF-7AC97F037400Q46418723-4A1E72E0-1977-4A36-A8B9-0DC0A016A255Q47112630-0B16605C-E830-4DAC-A9E5-9B6583B2FE67Q47837577-9205D2FD-5C9B-4814-9812-153C37325742Q48351089-01FEF3FA-B3D6-46A7-80C1-3F598255C010Q48972423-FB2BA01E-F26D-4EB6-91BA-B6E4B785FD84Q51141937-72C697B0-176D-4BF1-9086-B5D5378E86F8Q51788589-3478EB3D-5E46-4FC6-B519-1A676C346321Q55310138-71D1A8EC-54C7-44C5-B9D2-52FA32486BA5Q56860028-D314488A-FDB5-4545-B380-BAEA02170B71
P2860
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@ast
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@en
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@nl
type
label
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@ast
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@en
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@nl
prefLabel
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@ast
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@en
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@nl
P2093
P2860
P3181
P356
P1476
Pharmacogenetic-guided dosing ...... cenocoumarol and phenprocoumon
@en
P2093
Anke-Hilse Maitland-van der Zee
Anthonius de Boer
Rianne M F van Schie
Talitha I Verhoef
William K Redekop
P2860
P304
P3181
P356
10.1111/BCP.12220
P407
P50
P577
2014-04-01T00:00:00Z